Lipopolysaccharide (LPS) from the Gram-negative pathogen Porphyromonas gingivalis (Pg) stimulates cytokine secretion in immune cells, and thereby initiates the inflammation associated with periodontitis. Modulation of pro-inflammatory cytokine activity is a plausible therapeutic target in periodontal disease. Vasoactive intestinal peptide (VIP) has a role in immunoregulation, and has been identified as a molecule with therapeutically beneficial immunosuppressive effects in inflammatory and autoimmune conditions. We aimed to investigate the effect of VIP on immune responses induced by Pg LPS in vitro. VIP (10−8 M) significantly (P < 0.05) inhibits TNF-α production by human monocytic THP1 cells stimulated with Pg LPS. In parallel, we showed that VIP inhibits nuclear translocation of NFκB and c-Jun in a time-dependent manner, but does not decrease the expression of CD14 receptors. This is the first report to show the potential of VIP as an immunomodulator of Pg-stimulated inflammatory pathways in human monocytes.
Get full access to this article
View all access options for this article.
References
1.
Darveau RP, Pham TT, Lemley K, Reife RA, Bainbridge BW, Coats SR, et al. -2004-. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infect Immun72:5041–5051.
2.
Delgado M, Ganea D -2000-. Inhibition of IFN-gamma-induced Janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol165:3051–3057.
3.
Delgado M, Ganea D -2003-. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochem Biophys Res Commun302:275–283.
4.
Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP -1999a-. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol99:61–71.
5.
Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D -1999b-. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol162:1707–1716.
6.
Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D -1999c-. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol96:167–181.
7.
Delgado M, Pozo D, Martinez C, Leceta J, Calvo JR, Ganea D, et al. -1999d-. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol162:2358–2367.
8.
Dixon DR, Bainbridge BW, Darveau RP -2004-. Modulation of the innate immune response within the periodontium. Periodontol 200035:53–74.
9.
Duncan L, Yoshioka M, Chandad F, Grenier D -2004-. Loss of lipopolysaccharide receptor CD14 from the surface of human macrophage-like cells mediated by Porphyromonas gingivalis outer membrane vesicles. Microb Pathog36:319–325.
10.
Foster N, Hulme SD, Barrow PA -2003-. Induction of antimicrobial pathways during early-phase immune response to Salmonella spp. in murine macrophages: gamma interferon -IFN-gamma- and upregulation of IFN-gamma receptor alpha expression are required for NADPH phagocytic oxidase gp91-stimulated oxidative burst and control of virulent Salmonella spp. Infect Immun71:4733–4741.
11.
Foster N, Hulme SD, Barrow PA -2005-. Inhibition of IFN-gamma-stimulated proinflammatory cytokines by vasoactive intestinal peptide -VIP- correlates with increased survival of Salmonella enterica serovar typhimurium phoP in murine macrophages. J Interferon Cytokine Res25:31–42.
12.
Ganea D, Rodriguez R, Delgado M -2003-. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol49:127–142.
13.
Graves DT, Cochran D -2003-. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol74:391–401.
14.
Jotwani R, Pulendran B, Agrawal S, Cutler CW -2003-. Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur J Immunol33:2980–2986.
15.
Kitchens RL, Ulevitch RJ, Munford RS -1992-. Lipopolysaccharide -LPS- partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. J Exp Med176:485–494.
16.
Lamont RJ, Jenkinson HF -1998-. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev62:1244–1263.
17.
Leceta J, Martinez C, Delgado M, Garrido E, Gomariz RP -1996-. Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv Neuroimmunol6:29–36.
18.
Lindemann RA, Economou JS, Rothermel H -1988-. Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides. J Dent Res67:1131–1135.
19.
Linden GJ, Mullally BH, Burden DJ, Lamey PJ, Shaw C, Ardill J, et al. -2002-. Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol29:484–489.
20.
Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, et al. -2000-. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol164:4277–4285.
21.
McFarlane CG, Reynolds JJ, Meikle MC -1990-. The release of interleukin-1 beta, tumor necrosis factor-alpha and interferon-gamma by cultured peripheral blood mononuclear cells from patients with periodontitis. J Periodontal Res25:207–214.
22.
Nagasawa T, Kobayashi H, Aramaki M, Kiji M, Oda S, Izumi Y -2004-. Expression of CD14, CD16 and CD45RA on monocytes from periodontitis patients. J Periodontal Res39:72–78.
23.
Ogawa T -1993-. Chemical structure of lipid A from Porphyromonas -Bacteroides- gingivalis lipopolysaccharide. FEBS Lett332:197–201.
24.
Paquette DW, Williams RC -2000-. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 200024:239–252.
25.
Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J -2001-. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol167:5067–5076.
26.
Rossomando EF, Kennedy JE, Hadjimichael J -1990-. Tumour necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol35:431–434.
27.
Xin Z, Sriram S -1998-. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J Neuroimmunol89:206–212.
28.
Zhou Q, Desta T, Fenton M, Graves DT, Amar S -2005-. Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect Immun73:935–943.
